BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35624211)

  • 1. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
    Yeo AT; Rawal S; Delcuze B; Christofides A; Atayde A; Strauss L; Balaj L; Rogers VA; Uhlmann EJ; Varma H; Carter BS; Boussiotis VA; Charest A
    Nat Immunol; 2022 Jun; 23(6):971-984. PubMed ID: 35624211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
    Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
    Genome Med; 2024 Apr; 16(1):51. PubMed ID: 38566128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
    Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
    Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression.
    Chen X; Chen Y; Chen X; Wei P; Lin Y; Wu Z; Lin Z; Kang D; Ding C
    Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166534. PubMed ID: 36057370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
    Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
    bioRxiv; 2023 Dec; ():. PubMed ID: 36945572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival.
    Pan Y; Smithson LJ; Ma Y; Hambardzumyan D; Gutmann DH
    Oncotarget; 2017 May; 8(20):32977-32989. PubMed ID: 28380429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
    Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
    Front Immunol; 2020; 11():835. PubMed ID: 32457755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
    Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
    Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
    Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8
    Liu F; Zhou Q; Jiang HF; Zhang TT; Miao C; Xu XH; Wu JX; Yin SL; Xu SJ; Peng JY; Gao PP; Cao X; Pan F; He X; Chen XQ
    J Exp Clin Cancer Res; 2023 May; 42(1):118. PubMed ID: 37161450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
    Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
    Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha.
    De Vlaminck K; Romão E; Puttemans J; Pombo Antunes AR; Kancheva D; Scheyltjens I; Van Ginderachter JA; Muyldermans S; Devoogdt N; Movahedi K; Raes G
    Front Immunol; 2021; 12():777524. PubMed ID: 34917090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
    Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
    J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of single-cell transcriptomics reveals age-associated immune landscape of glioblastoma.
    Wu S; Li X; Hong F; Chen Q; Yu Y; Guo S; Xie Y; Xiao N; Kong X; Mo W; Wang Z; Chen S; Zeng F
    Front Immunol; 2023; 14():1028775. PubMed ID: 36761752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
    Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
    Front Immunol; 2022; 13():964898. PubMed ID: 35967394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
    Hasan T; Caragher SP; Shireman JM; Park CH; Atashi F; Baisiwala S; Lee G; Guo D; Wang JY; Dey M; Wu M; Lesniak MS; Horbinski CM; James CD; Ahmed AU
    Cell Death Dis; 2019 Mar; 10(4):292. PubMed ID: 30926789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
    Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
    Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.